AI Article Synopsis
- A significant number of women who are carriers of haemophilia exhibit similar bleeding tendencies to males with mild haemophilia, due to impaired factor VIII or IX genes.
- Data collected from Swedish treatment centers revealed that carriers with reduced or unknown factor activity experienced joint-related diagnoses at an earlier age and had a higher overall risk for joint issues compared to matched controls.
- The study highlights the need for regular clinical monitoring of haemophilia carriers, particularly those with reduced factor activity, to manage potential joint complications effectively.
Article Abstract
Background: A significant fraction of women with an impaired factor VIII or IX gene in the X chromosome, carriers of haemophilia, will have clotting factor activities corresponding to those seen in males with non-severe haemophilia, hence, experience an increased bleeding tendency. Data describing the long-term joint outcomes among carriers are limited. We compared the age at onset, frequency of joint-related diagnoses as well as joint surgery and related hospitalizations among carriers of haemophilia with sex- and birthdate-matched controls from the general population.
Methods: Carriers of haemophilia born 1941-2008 were identified through the haemophilia treatment centres' (HTCs) databases and the National Patient Register of Sweden. For each carrier, we included up to five individuals using the Swedish population register as comparisons. Data for the period 1987-2008 were obtained.
Results: Among 539 potential carriers identified, 213 had a known factor activity. Carriers with reduced factor activity and those with unknown factor activity had received their first joint-related diagnosis at a significantly earlier age than their comparisons. The same subgroups showed an overall 2.3- and 2.4-fold higher hazard for joint-related diagnoses compared with the general population. In addition, the hazards of joint-related outpatient hospitalization were 3.2-fold (95% CI: 1.2, 9.1) and 2.5-fold (95% CI: 1.6, 3.7). This was not observed for those with normal factor activity.
Conclusion: Carriers of haemophilia suffer a significant risk for joint comorbidities. This risk seems to correlate to the factor activity. Our findings underline the importance of regular clinical follow-up of carriers at HTCs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/hae.13831 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigation of a hemophilia family with one female hemophilia A patient and 12 male hemophilia A patients.
Ann Hematol
December 2024
Shandong Blood Center, Shandong Hemophilia Treatment Center, Jinan, China.
Hemophilia A (HA) is an X-chromosome-linked recessive genetic disorder. Female carriers may have bleeding symptoms, but rarely have moderate or severe disease. We identified a female patient with moderate HA by pedigree tracking and genetic testing in a HA family involving consanguineous marriage.
View Article and Find Full Text PDFThe history of women and hemophilia: a narrative review of evolving beliefs and testing practices.
J Thromb Haemost
December 2024
Queen's University, Kingston, Canada. Electronic address:
The history of hemophilia is well-documented, yet reports focus heavily on the male-perspective and severe forms of the disease. Although hemophilia was initially believed to only affect men with women seen as silent carriers, it is now universally acknowledged that women and girls can also be affected. In this narrative review, we track the progression of beliefs about women and hemophilia as documented in the literature from pre-1800's to the present time.
View Article and Find Full Text PDFClot waveform analysis in hemophilia carriers.
Blood Coagul Fibrinolysis
November 2024
Biological Hematology Department, Aziza Othmana Hospital, Tunis, Tunisia.
In recent years, there has been a growing interest in the activated partial thromboplastin time clot waveform analysis (APTT-CWA), which reflects clot formation. It was mainly studied in hemophilia and disseminated intravascular coagulation. The aim of this study was to evaluate the usefulness of APTT-CWA in hemophilia carriers.
View Article and Find Full Text PDFDesign of an international, phase IV, open-label study of simoctocog alfa in women/girls with hemophilia A undergoing surgery (NuDIMENSION).
Ther Adv Hematol
December 2024
Institute of Experimental Haematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Venusberg Campus 1, Gebäude 43, Bonn 53127, Germany.
Background: Although hemophilia A mainly affects males, carriers (defined as females with hemophilia A, as well as symptomatic or asymptomatic hemophilia A carriers) are at risk of excessive bleeding, particularly during trauma or during surgical procedures. Clinical trials have focused on male patients with severe disease, and data for females are limited. Improved, evidence-based treatment guidelines for management of hemophilia A carriers are required.
View Article and Find Full Text PDFAssessment of joint health in females with haemophilia: The carriers ultrasound project (CUP) study.
Haemophilia
November 2024
Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Miami-Miller School of Medicine, Miami, Florida, USA.
Introduction: The needs of haemophilia carriers (HC) have been historically overlooked. It is now recognised that HC manifests bleeding symptoms, including haemarthrosis. The natural history of joint health in HC is not yet defined.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!